🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the battle against drug-resistant strains of the infection, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are escalating globally, with figures suggesting over 82 million infections per year. Particularly high rates are seen in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the reality of rising global incidence, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in recent days for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers believe that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, also received approval in the same week. This medication, which is also used to treat UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This approval signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Outcomes and Worldwide Availability

As per results published in a prominent scientific publication, zoliflodacin eradicated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which uses two antibiotics. The research involved hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to register and commercialise the drug in many developing nations.

Doctors on the front lines have expressed optimism. Access to a easy-to-administer therapy like this is hailed as a "critical tool" for gonorrhoea control. This is viewed as vital to alleviate the strain of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.